Gastroenterology Endocrinology General Medicine Strong — validated in multiple cohorts; endorsed by EASL/EASD/EASO guidelines
NAFLD Fibrosis Score
Non-invasive score to identify significant fibrosis (F2–F4) or cirrhosis in patients with non-alcoholic fatty liver disease (NAFLD/MASLD), potentially avoiding liver biopsy.
References
- Angulo P, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Omega-3-acid ethyl esters · Omega-3 fatty acids
- Ivacaftor · CFTR Potentiator (Cystic Fibrosis — Gating Mutations)
- Elexacaftor / Tezacaftor / Ivacaftor · CFTR Triple Modulator (Cystic Fibrosis — F508del)
- Ivacaftor · CFTR Potentiator — Cystic Fibrosis
- Elexacaftor / Tezacaftor / Ivacaftor · CFTR Triple Modulator — Cystic Fibrosis
- Dornase Alfa (rhDNase) · Mucolytic — Cystic Fibrosis
Pathways
- Upper GI Bleeding · BSG Guidelines 2019; NICE NG141
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.